Cybin $175 million registered direct offering
The common shares are dual-listed on the NYSE American and Cboe Canada
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
ADC Therapeutics $60 million private placement
We advised ADC Therapeutics on the transaction involving its common shares and pre-funded warrants
Aveanna $90 million secondary offering
The shares are listed on the Nasdaq Global Select Market
RAPT Therapeutics $250 million follow-on offering
The shares are listed on the Nasdaq Global Market
Nurix Therapeutics $250 million stock offering
The stock is listed on the Nasdaq Global Market
GRAIL $325 million private placement
The PIPE included common stock and pre-funded warrants
Esperion Therapeutics follow-on offering
The shares are listed on Nasdaq
Turn Therapeutics direct listing
We advised Turn Therapeutics on its Nasdaq listing
Oruka Therapeutics $200 million at-the-market offering
We advised Oruka on the offering
Medtronic €1.5 billion notes offering
The investment-grade notes are due 2030 and 2045